Apo10 and TKTL1 in blood macrophages as non-invasive biomarkers for early detection of cervical cancer.

IF 4.8 2区医学 Q1 Medicine

Cellular Oncology Pub Date : 2025-07-28 DOI:10.1007/s13402-025-01092-3

Shuqing Wang, Zhiying Mao, Yuying Liu, Chunyan Lan, Lizhi Liu, Musheng Zeng, Chuanbo Xie

{"title":"Apo10 and TKTL1 in blood macrophages as non-invasive biomarkers for early detection of cervical cancer.","authors":"Shuqing Wang, Zhiying Mao, Yuying Liu, Chunyan Lan, Lizhi Liu, Musheng Zeng, Chuanbo Xie","doi":"10.1007/s13402-025-01092-3","DOIUrl":null,"url":null,"abstract":"Purpose: Apo10 and TKTL1 are tumor-associated markers reflecting impaired apoptosis and enhanced glycolysis respectively. This study aimed to evaluate the diagnostic potential of Apo10, TKTL1, and APT (a combination of Apo10 and TKTL1) in screening early-stage cervical cancer.Methods: A total of 152 patients with cervical cancer and 152 age-matched healthy controls were enrolled at Sun Yat-sen University Cancer Center from November 2020 to August 2023. Clinical data were collected from the Hospital Information System (HIS) and medical records, and blood samples were collected from all participants before treatment using epitope detection in monocytes (EDIM) technology 60 min after their last meal. Descriptive statistics and receiver operating characteristic (ROC) curves were used to compare the diagnostic performance of Apo10, TKTL1, and APT to those of conventional cervical cancer biomarkers (CEA, CA125, and SCC-A).Results: Most of the enrolled patients with cervical cancer had early-stage disease (70%) and squamous cell histology (84.9%). The Apo10, TKTL1, and APT levels were significantly higher in the cervical cancer group than in the control group (Apo10:139 vs. 132, TKTL1:121 vs. 114, APT: 260 vs. 246). We also found that Apo10, TKTL1, and APT showed superior diagnostic performance (AUC: 0.864, 0.865, 0.905) compared to traditional markers (CEA: 0.690, CA125: 0.594, SCC-A: 0.806). Sensitivity analysis revealed APT maintained high diagnostic value across tumor stages and in both HPV-negative (AUC = 0.967) and TCT-negative (AUC = 0.958) subgroups.Conclusion: Apo10, TKTL1, and APT outperform conventional biomarkers in detecting cervical cancer and may serve as reliable diagnostic indicators.","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13402-025-01092-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Apo10 and TKTL1 are tumor-associated markers reflecting impaired apoptosis and enhanced glycolysis respectively. This study aimed to evaluate the diagnostic potential of Apo10, TKTL1, and APT (a combination of Apo10 and TKTL1) in screening early-stage cervical cancer.

Methods: A total of 152 patients with cervical cancer and 152 age-matched healthy controls were enrolled at Sun Yat-sen University Cancer Center from November 2020 to August 2023. Clinical data were collected from the Hospital Information System (HIS) and medical records, and blood samples were collected from all participants before treatment using epitope detection in monocytes (EDIM) technology 60 min after their last meal. Descriptive statistics and receiver operating characteristic (ROC) curves were used to compare the diagnostic performance of Apo10, TKTL1, and APT to those of conventional cervical cancer biomarkers (CEA, CA125, and SCC-A).

Results: Most of the enrolled patients with cervical cancer had early-stage disease (70%) and squamous cell histology (84.9%). The Apo10, TKTL1, and APT levels were significantly higher in the cervical cancer group than in the control group (Apo10:139 vs. 132, TKTL1:121 vs. 114, APT: 260 vs. 246). We also found that Apo10, TKTL1, and APT showed superior diagnostic performance (AUC: 0.864, 0.865, 0.905) compared to traditional markers (CEA: 0.690, CA125: 0.594, SCC-A: 0.806). Sensitivity analysis revealed APT maintained high diagnostic value across tumor stages and in both HPV-negative (AUC = 0.967) and TCT-negative (AUC = 0.958) subgroups.

Conclusion: Apo10, TKTL1, and APT outperform conventional biomarkers in detecting cervical cancer and may serve as reliable diagnostic indicators.

查看原文本刊更多论文

血巨噬细胞中Apo10和TKTL1作为宫颈癌早期检测的非侵入性生物标志物

目的：Apo10和TKTL1分别是反映细胞凋亡受损和糖酵解增强的肿瘤相关标志物。本研究旨在评估Apo10、TKTL1和APT （Apo10和TKTL1的组合）在筛查早期宫颈癌中的诊断潜力。方法：中山大学癌症中心于2020年11月至2023年8月招募了152例宫颈癌患者和152例年龄匹配的健康对照。从医院信息系统（HIS）和病历中收集临床数据，并在最后一餐后60分钟使用单核细胞表位检测（EDIM）技术采集所有参与者治疗前的血液样本。采用描述性统计和受试者工作特征（ROC）曲线比较Apo10、TKTL1和APT与常规宫颈癌生物标志物（CEA、CA125和SCC-A）的诊断效能。结果：入组的宫颈癌患者以早期病变（70%）和鳞状细胞组织学（84.9%）为主。宫颈癌组Apo10、TKTL1和APT水平明显高于对照组（Apo10:139 vs. 132, TKTL1:121 vs. 114, APT: 260 vs. 246）。我们还发现，Apo10、TKTL1和APT与传统标记（CEA: 0.690、CA125: 0.594、SCC-A: 0.806）相比，具有更好的诊断效果（AUC分别为0.864、0.865、0.905）。敏感性分析显示，APT在不同肿瘤分期、hpv阴性（AUC = 0.967）和tct阴性（AUC = 0.958）亚组均保持较高的诊断价值。结论：Apo10、TKTL1、APT在检测宫颈癌方面优于常规生物标志物，可作为可靠的诊断指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

10.40

自引率

1.50%

发文量

审稿时长

16 weeks

期刊介绍： The Official Journal of the International Society for Cellular Oncology Focuses on translational research Addresses the conversion of cell biology to clinical applications Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.